These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6812108)

  • 1. Chronic benztropine and haloperidol administration induce behaviorally equivalent pharmacological hypersensitivities separately but not in combination.
    Carey RJ; De Veaugh-Geiss J
    Psychopharmacology (Berl); 1982; 76(4):341-5. PubMed ID: 6812108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation.
    Carvey PM; Hitri A; Goetz CG; Tanner CM; Klawans HL
    Life Sci; 1988; 42(22):2207-15. PubMed ID: 3374255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment.
    Smith RC; Davis JM
    Psychopharmacol Commun; 1975; 1(3):285-93. PubMed ID: 1241453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of central dopaminergic receptors of morphine: effect of haloperidol, apomorphine or benztropine.
    Puri SK; Reddy C; Lal H
    Res Commun Chem Pathol Pharmacol; 1973 Mar; 5(2):389-401. PubMed ID: 4735501
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of benztropine mesylate on haloperidol-induced prolactin secretion and serum haloperidol levels in rats.
    Rosenberg JM; Sideman M; Kampa IS; McGuire H; Kampa L
    J Pharm Sci; 1984 Dec; 73(12):1833-5. PubMed ID: 6527272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity.
    Carvey PM; Kao LC; Tanner CM; Goetz CG; Klawans HL
    Eur J Pharmacol; 1986 Jan; 120(2):193-9. PubMed ID: 3948919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term application of haloperidol: effects on dopamine and acetylcholine receptors.
    Stock G; Kummer P
    Int Pharmacopsychiatry; 1981; 16(3):144-53. PubMed ID: 6797983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops.
    Kinon BJ; Kane JM
    Psychopharmacology (Berl); 1989; 98(4):465-71. PubMed ID: 2505286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
    Seeger TF; Thal L; Gardner EL
    Psychopharmacology (Berl); 1982; 76(2):182-7. PubMed ID: 6805029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrastriatal injection of kainic acid prevents the development of postsynaptic dopamine receptor hypersensitivity after chronic haloperidol treatment.
    Zarkovsky AM; Nurk AM; Rägo LK; Allikmets LH
    Neuropharmacology; 1982 Feb; 21(2):155-8. PubMed ID: 7199630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of atropine, benztropine and diphenhydramine on the reversal of haloperidol induced suppression of self-stimulation.
    Carey RJ
    Pharmacol Biochem Behav; 1982 Oct; 17(4):851-4. PubMed ID: 7178193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
    Waddington JL; Gamble SJ
    Eur J Pharmacol; 1980 Oct; 67(4):363-9. PubMed ID: 7192633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of benztropine on haloperidol-induced prolactin secretion.
    Lal S; Mendis T; Cervantes P; Guyda H; DeRivera JL
    Neuropsychobiology; 1979; 5(6):327-31. PubMed ID: 503307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of benztropine on the diurnal prolactin responses to haloperidol.
    Nathan RS; Perel JM; McCarthy T; Jarrett DB
    Psychoneuroendocrinology; 1985; 10(1):71-6. PubMed ID: 3889966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide.
    Hassan MN; Reches A; Kuhn C; Higgins D; Fahn S
    Clin Neuropharmacol; 1986; 9(1):71-8. PubMed ID: 3829008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of haloperidol induced deficits in self-stimulation by anti-Parkinsonian drugs.
    Carey RJ
    Behav Brain Res; 1983 Dec; 10(2-3):405-11. PubMed ID: 6318780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.
    Montanaro N; Dall'Olio R; Gandolfi O; Vaccheri A
    Eur J Pharmacol; 1982 Jun; 81(1):1-9. PubMed ID: 6889533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of benztropine mesylate on the prolactin response to haloperidol.
    Halbreich U; Sachar EJ; Nathan RS; Asnis GM; Halpern FS
    Psychopharmacology (Berl); 1980; 72(1):61-5. PubMed ID: 6781007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of chronic lithium on behavioral and biochemical indices of dopamine receptor supersensitivity in the rat.
    Pittman KJ; Jakubovic A; Fibiger HC
    Psychopharmacology (Berl); 1984; 82(4):371-7. PubMed ID: 6427831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.